Peninsula Cancer Network
(North, East & West Devon, South Devon & Torbay, Cornwall, Somerset )
Urological Cancer Network Site Specific Group
Constitution
VERSION CONTROL
THIS IS A CONTROLLED DOCUMENT - PLEASE ARCHIVE ALL PREVIOUS VERSIONS ON RECEIPT OF THE CURRENT VERSION.
Please check the website for the latest version available:
www.swscn.org.uk
VERSION
0.1 v2
0.1 v3
DATE ISSUED
May 2015
November 2015
SUMMARY OF CHANGE
2nd draft
3rd draft
OWNER
PCN Urology NSSG
PCN Urology NSSG
1
Peninsula Cancer Network Uro-oncology Constitution 2015
Constitution of the Peninsula Cancer Network
Urological Cancer Site Specific Group
Agreement cover sheet
This constitution was prepared by:
Rob Mason (Acting) Chair of the Peninsula Cancer Network Urology SSG, Consultant Urologist, South
Devon Healthcare NHS Trust
Liz Boylan – Peninsula Cancer Network SSG Manager
This constitution has been agreed by:
Name
Position
Organisation
Rob Mason
Consultant Urologist/Chair
South Devon Healthcare NHS Foundation Trust
(SDHT)
Martin Moody
Consultant Urologist
Northern Devon Healthcare NHS Trust (NDHT)
Elizabeth Waine
Consultant Urologist
Royal Devon & Exeter NHS Foundation Trust
(RDE)
Paul HunterCampbell
Consultant Urologist
South Devon Healthcare NHS Trust (SDHT)
Consultant Urologist
Royal Cornwall Hospitals NHS Trust (RCHT)
Consultant Urologist
Taunton & Somerset NHS Foundation Trust
(TST)
Yeovil District Hospital NHS Trust (YDHT)
Mark Mantle
Nick Burns-Cox
Date agreed
2
Peninsula Cancer Network Uro-oncology Constitution 2015
Contents
1.
Statement of Purpose
2.
Terms of Reference for the Group
3.
Structure and Function
3.1
Role and Function of the Group
3.2
Network Configuration
3.3
3.4
Network Group Members
Local Urological Cancer Teams
3.5
4
14-1C-101g
14-1C-101g
4
5
5
14-1C-101g
14-1C-101g, 14-1C-102g
6
14-1C-101g, 14-1C-102g
8
Specialist Urological Cancer Teams
14-1C-101g, 14-1C-102g
9
3.6
Network Group Membership
14-1C-102g, 14-1C-103g
9
3.7
Group Meetings
14-1C-103g
9
3.8
Work Programme and Annual Report
Coordination of Care/Patient Pathway
14-1C-104g
10
4.
6
10
4.1
Primary Care Referral Guidelines
10
4.2
Referral Guidelines for Patients moving between Teams
10
4.3
Clinical Guidelines
11
4.3.1
Clinical Guidelines for Kidney Cancer
14-1C-105g
11
4.3.2
Clinical Guidelines for Bladder Cancer
14-1C-106g
11
4.3.3
Clinical Guidelines for Prostate Cancer
14-1C-107g
11
4.3.4
Clinical Guidelines for Testicular Cancer
14-1C-108g
11
4.3.5
Clinical Guidelines for Penile Cancer
14-1C-109g
11
4.3.6
Chemotherapy Treatment Algorithms
14-1C-110g
11
4.4
Patient Pathways for Kidney Cancer
14-1C-111g
12
4.4.1
Patient Pathways for Bladder Cancer
14-1C-112g
12
4.4.2
Patient Pathways for Prostate Cancer
14-1C-113g
12
4.4.3
Patient Pathways for Testicular Cancer
14-1C-114g
12
4.4.4
Patient Pathways for Penile Cancer
14-1C1-115g
12
5.
Patient Experience
14-1C-116g
12
6.
Clinical Outcomes/Indicators
12
6.1
Clinical Outcomes Indicators and Audits
14-1C-117g
12
6.2
Discussion of Clinical Trials
14-1C-118g
12
Data Collection
12
7.1
Network-wide Minimum Data Set
12
7.2
Network Policy on collection of MDS
12
8.
Distribution of Guidelines & Protocols
13
App 1
Terms of Reference
14
7.
3
Peninsula Cancer Network Urology Constitution 2015
1. Statement of Purpose
The Peninsula Cancer Network exists to secure equal access to high quality care for all cancer
patients; strive for better clinical outcomes and improve the experience of patients, their carers
and families throughout screening, diagnosis, treatment, aftercare and survival.
The Network has an increasing role in the prevention of cancer and reducing health
inequalities. To achieve these goals it collaborates with all healthcare providers,
commissioners, patients and their carers throughout Devon, Cornwall and the Isles of Scilly.
The Peninsula Cancer Network serves a population of 1.7 million people and is comprised
of the following organisations:
Clinical Commissioning Groups (CCGs)
Northern, Eastern & Western Devon CCG
South Devon & Torbay CCG
NHS Kernow CCG
NHS Somerset CCG
Acute Hospitals
Northern Devon Healthcare NHS Trust
Plymouth Hospitals NHS Trust
Royal Cornwall Hospitals NHS Trust
Royal Devon & Exeter NHS Foundation Trust
South Devon Healthcare NHS Foundation Trust
Taunton & Somerset NHS Foundation Trust
Yeovil District Hospital NHS Foundation Trust
Hospices
Hospiscare, Exeter
Mount Edgcumbe Hospice, Cornwall
North Devon Hospice
Rowcroft Hospice, Torquay
St Julia’s Hospice, Cornwall
St Luke’s Hospice, Plymouth
St Margaret’s Hospice, Taunton & Yeovil
The following document outlines the constitution, roles and responsibilities of the Group.
2. Terms of Reference for the Group 14-1C-101g
In response to the publication of the Manual for Cancer Services (2004) a number of
clinical sub- Groups were established to address services for specific types of cancer.
4
Urology NSSG Constitution draft v0.3 – November 2015
Network Site Specific Groups have collective responsibility, delegated by the Network Executive
Board, for coordination and consistency across the Network for cancer policy, practice
guidelines, audit, research and service improvement for each type of cancer.
Network site specific Groups are multidisciplinary with representation from professionals across
the patient care pathway as well as involvement and representation from patient and carers. (see
Appendix 1)
3. Structure and Function
3.1 Role and Function of the Group
Network Site Specific Groups have been established to:
 Act as the Network Executive Board’s primary source of tumour site specific clinical opinion for the
network;
 Advise and consult on service planning to ensure services are in line with national guidance in
order to promote high quality care and reduce inequalities in service delivery;
 Ensure Network decisions become integrated into local practice;
 Monitor progress on meeting National Cancer Standards and ensure action plans agreed following
Peer Review are implemented;
 Promote links between teams and other relevant Network Groups.
The key objectives of the Urology Network Site Specific Group will be to:
 Establish common referral and clinical guidelines for the Network;
 Agree a minimum data set for urological cancers and a policy for consistent data collection
across the Network;
 Engage in service improvement by using appropriate mapping and other service improvement
processes to understand patient flows and make recommendations for improvement to the
patient pathway.
 Agree and support an annual audit programme both at regional and local level ;
 Agree a common approach to research & development working with the Network Research
Team, participating in nationally recognised studies whenever possible;
 Consult with relevant cross-cutting groups on issues involving chemotherapy, radiotherapy,
cancer imaging, histopathology, laboratory investigation and specialist palliative care;
 Agreeing clinical, referral, imaging and pathology guidelines for urological cancer. To
subsequently review, agree and update these guidelines on a regular basis and to audit the
implementation of these guidelines.
 Identifying, compiling and agreeing a list of clinical trials for urological cancers and facilitate the
means by which patients managed by the MDTs may be entered into trials. MDT responses to
the list should be discussed at NSSG meetings.
 Support the development of education and training programmes for teams;
 Support effective patient and carer involvement in service planning and delivery;
 Produce an annual work plan.
5
Urology NSSG Constitution draft v0.3 – November 2015
3.2 Network Configuration 14-1C-101g
Membership of the Group will be multi-disciplinary in nature with representation from professionals
across the care pathway. All core and extended members of the relevant Acute Trust MDT(s) are
invited to participate in Group activities via group meetings, working parties and email
communications as appropriate.
The Chair of the Group will be elected from within the membership of the Group. The term of office will
be for two years.
The members will work towards developing patient and carer involvement in the group. Patient and
carer representatives will be appointed whenever possible. A patient champion and information
lead will be identified from within the group who will have specific responsibility for patient issues
and information for patients and carers.
A clinical trial recruitment lead will be identified from within the membership of the group who will
work with the research network team and liaise with MDT representatives on research issues.
3.3 Network Group Members 14-1C-101g, 14-1C-102g
Urology Network Site Specific Group Chairperson
Rob Mason
Consultant Urologist
South Devon Healthcare NHS
Trust
Consultant Clinical Oncologist
Taunton & Somerset NHS
Foundation Trust
NSSG Trial Recruitment Clinical Lead
Mohini Varughese
Patient Champion & Information Lead
vacant
Patient and Carer Representatives
To be advised
Northern Devon Healthcare NHS Trust (NDHT)
Consultant Urologist
Martin Moody
McBride Tracey
Clinical Nurse Specialist
Catherine Dring
Clinical Nurse Specialist
MDT Lead
Plymouth Hospitals NHS Trust (PHT)
Paul Hunter-Campbell
Lead Cancer Clinician
Andrew Dickinson
Consultant Urologist
Vanessa Wilcox
Uro-oncology Nurse Specialist
Martin Highley
Consultant Medical Oncologist
Jane Ripley
Frances McCormick
Clinical Nurse Specialist
Paul McInerney
Consultant Urologist
Francis Daniel
Consultant Clinical Oncologist
MDT Lead
Consultant Histopathologist
6
Urology NSSG Constitution draft v0.3 – November 2015
Richard Pearcy
Consultant Urologist
Sarah Pascoe
Consultant Clinical Oncologist
Salvatore Natale
Associate Specialist In Urology
Anna Wilson
Clinical Nurse Specialist
Esther McLarty
Consultant Urological Surgeon
Henry Sells
Consultant Urologist
Royal Cornwall NHS Hospitals Trust (RCHT)
Lead Cancer Clinician
Mark Mantle
Wendy Meyers
Clinical Nurse Specialist
Robert Cox
Consultant Urological Surgeon
Richard Ellis
Consultant Oncologist
Deborah Victor
Clinical Nurse Specialist
Alastair Thomson
Consultant Clinical Oncologist
John McGrane
Consultant Oncologist
MDT Lead
Royal Devon & Exeter NHS Foundation Trust (RDE)
Elizabeth Waine
Consultant Urologist
Malcolm Crundwell
Consultant Urologist
Karen Green
Clinical Nurse Specialist
Richard Guinness
Consultant Radiologist
Denise Sheehan
Consultant Clinical Oncologist
Claire Turner
Clinical Nurse Specialist
Jane Billing
Clinical Nurse Specialist
John McGrath
Consultant Urologist
Mark Stott
Consultant Urologist
Carole Brewer
Consultant Clinical Geneticist
MDT Lead
South Devon NHS Foundation Trust (SDHT)
Rob Mason
Lead Cancer Clinician
Seamus MacDermott
Consultant Urologist
Gillian Dell
Clinical Nurse Specialist
Doretta Boone
Urology Nurse Practitioner
Anna Lydon
Consultant Oncologist
Anne Carroll
Clinical Nurse Specialist
Prostate Specialist & Research
Radiographer
Taunton & Somerset NHS Foundation Trust (TST)
Consultant Urologist
Nick Burns-Cox
MDT Lead
Linda Welsh
Julia Pollard
Clinical Nurse Specialist
Ru Macdonagh
Consultant Urologist
MDT Lead
7
Urology NSSG Constitution draft v0.3 – November 2015
Mohini Varughese
Consultant Clinical Oncologist
Emma Gray
Consultant Clinical Oncologist
John Graham
Consultant Medical Oncologist
Yeovil District Hospitals NHS Foundation Trust (YDHT)
Tim Porter
Consultant Urologist
Chris Parker
Consultant Clinical Oncologist
Susan Adams
Consultant Pathologist
Karen Moffett
Urological Clinical Nurse Specialist
CCG Managers for Cancer
NHS NEW Devon CCG Western Locality
Lynne Kilner
NHS NEW Devon CCG Eastern Locality
Yash Patel
NHS NEW Devon CCG Northern Locality
Sara Wright
NHS South Devon & Torbay CCG
Emma Herd
NHS Kernow CCG
Andy Gordon
NHS Somerset CCG
Rachel Rowe
N.B. All Core Members of MDTs to be invited to attend NSSG Meetings.
3.4 Local Urological Cancer Teams 14-1C-101g, 14-1C-102g
Local Teams
Northern Devon Healthcare NHS
Trust (NDHT)
Plymouth Hospitals NHS Trust (PHT)
Royal Cornwall Hospitals NHS Trust
(RCHT)
Royal Devon & Exeter NHS
Foundation Trust (RDE)
South Devon Healthcare NHS
Foundation Trust (SDHT)
Taunton & Somerset NHS
Foundation Trust (TST)
MDT Lead Clinician
Locality
Referring CCGs
population
164,997
Martin Moody
NHS NEW Devon CCG
Northern locality
Paul Hunter-Campbell 349,481
NHS NEW Devon CCG
Western locality
534,503
Mark Mantle
NHS Kernow CCG
Malcolm Crundwell
383,040
Rob Mason
286,000
Nick Burns-Cox
544,000
Yeovil District Hospital NHS
Foundation Trust (YDHT)
NHS NEW Devon CCG
Eastern locality
NHS South Devon & Torbay
CCG
NHS Somerset CCG
NHS Somerset CCG
Total 2,262,021
8
Urology NSSG Constitution draft v0.3 – November 2015
3.5 Specialist Urological Cancer Teams 14-1C-101g, 14-1C-102g
Local Teams
MDT Lead
Clinician
Paul HunterCampbell
Plymouth Hospitals
NHS Trust (PHT)
Catchment
population
883,984
Royal Devon & Exeter NHS Malcolm Crundwell 1,378,037
Foundation Trust (RDE)
Total
Referring Local
MDTs
PHT
RCHT
RDE
NDHT
SDHT
TST
YDH
Referring CCGs
NEW Devon CCG
Western Locality
NHS Kernow CCG
NEW Devon CCG
Eastern Locality
Somerset CCG
2,262,021
3.6 Network Group Membership 14-1C-102g, 14-1C-103g
The Chair (Rob Mason) has been elected from within the membership of the group. The term of
office will be two years.
The group will work towards developing patient and carer involvement and will appoint patient and
carer representatives whenever possible. In addition to this, a member of the group will be
identified who will have specific responsibility for patient issues and information for patients and
carers. Mohini Varughese has been appointed cancer research sub specialty lead and assumes
responsibility for recruitment to trials.
3.7 Group Meetings 14-1C-103g
Meetings will be held twice per annum as a minimum. The group agrees to operate under the Terms of
Reference (Appendix 1). All members will be informed of meeting dates and location and be included
in distribution of the Agenda and Minutes. Minutes, actions and notes of the group meetings will be
circulated to all members, trust management teams and other interested parties. They will also be
published on the SWSCN website
http://www.swscn.org.uk/networks/cancer/site-specific-groups/peninsula-site-specificgroups/urology-ssg
Records of attendance will be maintained and shared with the Cancer Unit Managers in order to inform
them of their trust’s representation at network level. Liz Boylan, Peninsula Cancer Network Manager
and Mel Chandler, Administrative Assistant, will provide managerial and administrative support at
group meetings.
3.8 Work Programme and Annual Report 14-1C-104g
The group will produce an Annual Work Programme for Urology and submit an entry to the Network
Annual Report.
9
Urology NSSG Constitution draft v0.3 – November 2015
4. Coordination of Care/Patient Pathways
4.1 Primary Care Referral Guidelines
Primary Care practitioners will refer all patients defined by the “urgent, suspicious of cancer”
guidelines for urological cancer to the contact point of a single local urological team.
4.2 Referral Guidelines for Patients moving between Teams
All new urological cancer patients should be discussed first in the locality MDT most appropriate for
that individual patient. This is here termed the first MDT, and this MDT will usually assume lead
responsibility for the patient.
In certain circumstances it may be appropriate for an onward referral to be made from the first MDT
to a second MDT within or outside the Network. These are categorised below according to the
indication for the referral.
What follows is not intended to be a complete list of possible indications for referral, and it is
assumed that in all circumstances the locality MDT will act in the best interests of each patient for
which it has lead responsibility, making onward referrals as necessitated by the clinical
circumstances.
Referral to another specialist for further tests or treatment
Many staff participate in more than one urological cancer MDT. It is not necessary for cases to be
discussed at the second MDT if a patient is simply attending the centre for specialist investigations
or treatment not available to the locality MDT (for instance radiotherapy or surgery). However,
these cases may be discussed at the second MDT if the person receiving the referral from the first
MDT feels that it would be helpful.
Good communication with the first MDT will be particularly important in this optional situation. In
this situation the first MDT will consider the second MDT’s recommendations carefully, while
maintaining lead MDT responsibility.
Patients with synchronous cancers at urological and other site
Such patients will be discussed in the Urological MDT. Lead responsibility will be shared with the other
site-specific MDT, until it becomes clear which MDT would be best to lead in each individual case.
Second opinion requested by first MDT or patient
All such cases must be discussed at the second MDT. Both the referring and second MDT
recommendations will be considered with each patient to develop the treatment plan. The outcome
of those discussions will determine the most appropriate MDT to lead the patient’s further care.
Referring clinicians should ensure that all relevant information is provided to facilitate the continuity
of care and avoid unnecessary delays.
The Peninsula Tertiary Referral Form (TRF01) should be used when referring patients to another
10
Urology NSSG Constitution draft v0.3 – November 2015
Acute Trust for specialist investigation or treatment and sent within one working day of the referral
being made.
4.3 Clinical Guidelines
The Group has agreed to adopt the current NICE guidelines for:
 Bladder Cancer 14-1C-106g
 Prostate Cancer 14-1C-107g
 Kidney Cancer 14-1C-105g
 Testicular Cancer 14-1C-108g

Penile Cancer (in which the Group signs up to the guidelines produced by the Avon,
Somerset & Wiltshire Network).
14-1C-109g
Network guidelines will be reviewed at least every three years or on the publication of new guidance.
It is the responsibility of the Chair of the Group to ensure that all Network guidelines are up to
date and reflect current practice.
Penile Cancer 14-1C-109g, 14-1C-101g
The named nominated local leads and MDTs who can undertake biopsy, local follow up and some
of the cancer management care of patients with penile cancer as agreed by the NSSG and the Chair
of the Supra Network Group are:
Name
Richard Pearcy
John Palmer
Role
Consultant Urologist
Consultant Plastic Surgeon
MDT
Plymouth NHS Hospitals Trust
RD&E
Chemotherapy Treatment Algorithms 14-1C-110g
TBA
Patient Pathways for Kidney Cancer 14-1C-111g
TBA
Patient Pathways for Bladder Cancer 14-1C-112g
TBA
Patient Pathways for Prostate Cancer 14-1C-113g
TBA
Patient Pathways for Testicular Cancer 14-1C-114g
TBA
Patient Pathways for Penile Cancer 14-1C-115g
TBA
11
Urology NSSG Constitution draft v0.3 – November 2015
Patient Experience
14-1C-116g
TBA
Clinical Outcomes/Indicators
Clinical Outcomes Indicators and Audits 14-1C-117g
TBA
Discussion of Clinical Trials 14-1C-118g
TBA
Data collection
Network-wide Minimum Data Set
All Trusts have previously confirmed their compliance with data collection requirements for
cancer waiting times and the Cancer Registry. The group has also adopted the dataset of the
British Association of Urological Surgeons. Together these constitute the MDS for the Urological
Group
Go to link below for MDS:
http://www.mycancertreatment.nhs.uk/wpcontent/themes/mct/uploads/2012/09/resources_measures_Urology_April2013.pdf ???
Network Policy for Collection of MDS
The Acute Trust first seeing a patient for a particular month or quarter is responsible for ensuring
that the mandated data fields are complete on the database by the national deadline.
The Acute Trust first treating or giving subsequent treatment to a patient in a particular month or
quarter is responsible for ensuring that the mandated data fields regarding that patient are
complete on the database by the national deadline.
The multidisciplinary team responsible for the care of the patient should ensure that information is
made available to allow it to be recorded prospectively and electronically.
Cancer Services teams in each Acute Trust should ensure that the information is transferred within
the timescales specified and should establish robust lines of communication with their colleagues in
other Acute Trusts.
8. Distribution of Guidelines and Protocols
Once agreed by the NSSG, documents will be circulated to all core and extended members of the local
MDTs. The MDT Lead for each locality is responsible for forwarding them to relevant clinical
colleagues within their organisation and publishing on local document libraries where applicable. All
network agreed documents will be added to the Network website
http://www.swscn.org.uk/networks/cancer/site-specific-groups
12
Urology NSSG Constitution draft v0.3 – November 2015